

The Antiseptic

Estd. 1904

Indexed in
IndMED

A MONTHLY JOURNAL OF MEDICINE AND SURGERY


Email: admin@theantiseptic.in

www.theantiseptic.in

Vol. 116 • No. 4

APRIL 2019

ISSN 0003-5998 • ₹ 100



Human Papilloma Virus Vaccine

→ Page No : 20

HEALTH, HEALTH AND HEALTH FOR ALL



**Subscribe
Today**

"HEALTH" is a Monthly Publication devoted to Healthful Living.
"HEALTH" CARRIES Pictorial articles on

- DIET ■ NUTRITION ■ INFANT CARE & NURSING ■ BEAUTY
- DISEASE PREVENTION ■ HYGIENE ■ MENTAL HEALTH

"Health" : A Reliable instructor and adviser to every one who is health conscious

YES, I would like to Subscribe to → "Health"

One Year Subscription : ₹ 240/-

Mode of Payment : DD / Cheque / MO / NEFT
in favour of **Professional Publications Pvt. Ltd.**,
Payable at **Madurai**.

Account No. 268109000188090

IFSC Code: CIUB0000268 **Bank**: City Union Bank

Branch: TVS Nagar, Madurai-625003

Send your subscription to :
Professional Publications (P) Ltd.,
21, "Lakshmi" Sathyasai Nagar,
Madurai - 625 003. Tamilnadu.
Ph: 0452 - 2692939 / 4378300
Mob: +91 72000 84864
Email: admin@theantiseptic.in
Website: www.theantiseptic.in

The Antiseptic

Estd. 1904
A MONTHLY JOURNAL OF MEDICINE AND SURGERY

Founded by

Dr. U. RAMA RAO

Editor and Publisher

Dr. R. LAKSHMIPATHY

Executive Editor

Dr. S. VEMBAR

ADVISORY BOARD

Dr. K.V. Thiruvengadam MD

Dr. Sam C. Bose MS, M.Ch.

Dr. K. Srinivasan, MD, DM, PhD, FRCP, (E&G), FICA, FAMS

Dr. N. Kasirajan MD

Dr. N. Hariharasubramanian MD, Ph.D

Dr. N. Mohandas MD, DM, (Nephro)

Dr. Revathy Janakiram MD DGO MNAMS FICMCH FICOG

Dr. Shailesh Jain MS, MCh.

Dr. Sanjay Agrawal MBBS, MSC, MBA

Dr. Usha Giridhar M.D.S.

Dr. J. Jeyavenkatesh BSMS, MD

Dr. J. Sangumani MBBS, MD

Dr. R. Premalatha MD DGO DNB FRCOG

Dr. S. Meenakshi Sundaram MD, DM

Overseas Editor Dr. K. Ramasubbu

Single Copy Rs.100/-

Annual Subscription Rs. 1200/-

Rates include Postage. Cheques / D.D. to be drawn in favour of Professional Publications (P) Ltd., Madurai - 625 003, Tamilnadu. Ph: 0452 - 4378300, 2692939
Mobile No: 72000 84864

email: admin@theantiseptic.in

Publisher's Note

Dear Doctors,

The Antiseptic goes Digital Also!

"The Antiseptic" a monthly publication devoted to the cause of medical practice with an emphasis on general practice since 1904, has to its credit more than 100 years of uninterrupted dedicated service to Indian Medical Fraternity.

As one grows older, the dependence on drugs for relief of pain and suffering increases while the body becomes less efficient in handling the medicines and excreting them, resulting in greater drug interactions and cumulative adverse effects on the kidneys, liver, heart and brain. Therefore, utmost judiciousness is required in prescribing drugs for the elderly.

Month after month especially general physicians rely on **The Antiseptic** for breakthrough research at the intersection of biomedical science and clinical practice. Its peer-reviewed research and interactive clinical contents make it a must-read for physicians, educators, and the global medical community.

To keep abreast with the fast developing technology and digital trends **The Antiseptic** goes digital as well.

Launched from August 2016, onwards www.theantiseptic.in the most cutting-edge, website offers specialists, general physicians, and other health professionals the most robust and integrated medical information on medicine and surgery.

Welcome to www.theantiseptic.in

With warm regards,

Yours cordially



Dr. R. LAKSHMIPATHY

PUBLISHER

Madurai

20. 03. 2019

Printed by **L. Saroja**, Partner on behalf of **M/S. Sree Vinayaga Screens**, Edited and published by **Dr. R. Lakshmi Pathy** Sri Ram, 27, Sathya Sai Nagar, Madurai - 625 003 on behalf of **M/S. Professional Publications (P) Ltd**, and printed at 12A/1, Subramania Pillai Street, Madurai - 625 010 and published at 21, Lakshmi Sathya Sai Nagar, Madurai-625 003. Executive Editor **Dr. S. Vembar, MBBS, M. Sc.**, is responsible for selection of articles and news under PRB Act.

Note to Subscribers

THE ANTISEPTIC is not responsible for any loss in postal transit, as copies are sent by ordinary book-post. However replacement in such cases will be made only if claims are received within the month of issue. Not notifying the change of address or incomplete address will not qualify for replacement of copies.

EDITORIAL

Iron Metabolism05

GENERAL

Probiotics: Are they risk-free? *Sanjay Agrawal*07

Overexploitation of Himalayan Viagra will lead to extinction
Anshul Tomar, Vijay Thawani12

**Transinguinal Preperitoneal (TIPP) Meshplasty in the Management of Inguinal Hernia:
A Retrospective study of 50 cases at VSSIMSAR, Burla**
Harekrishna Majhi, Sandeep Ku. Das, Bhupesh Kumar Nayak, Akshay Ku. Behera14

CAR T - Cell Therapy in Cancer
Devvrat Raghuvanshi, Vijay Thawani18

HPV Vaccine – A Miraculous Invention! *Revathy Janakiram*20

The paramedian forehead flap: workhorse in reconstruction on external nose
Sudhir M. Naik, Vidya H., Sarika Sudhir Naik22

Artificial Intelligence and Pharmacovigilance
Rimjhim Sahu, Vijay Thawani24

**“Transoral transtonsillar styloidectomy”: A minimally invasive technique for
stylohyoid syndrome**
Sarika Sudhir Naik, Sudhir M. Naik, Vidya H.26

ALTERNATIVE MEDICINE

Treatment Modalities of Haemorrhoids
Kulkarni N.H., Maladkar C.S., Sachin N. Patil, Sarma J.K.29

Panchakarma-Preventive and Healing Therapies in Ayurveda
Renuga Suresh V.34

**Ayurvedic Pharmacological Potential of Brihat Yogaraja Guggulu –
An Herbo-Mineral Medicine** *Maladkar C.S.*37

Role of yoga on mental health and physical fitness in school going children
Dhananjay Dilip Deshmukh41

A Literary Review of Dwadashashana Pravichara
Shamkumar Krishnarao Karvekar44

Occasional Review46

Gleanings47

Glimpse into history48

Case of the month49

Medi Quiz50

Iron Metabolism

The total body iron in a 70 kg man is about 4 gms. Body absorbs r/mg/daily to maintain equilibrium. The internal requirement of iron is about 20-25 mg. About 20mg for iron synthesis and degradation and another 5mg for other needs. This daily turnover passes through the plasma for reutilization. Iron in excess of these requirements is deposited in body stores as ferritin or haemosiderin.

Iron absorption is an active process, in the proximal small intestine. The absorptive cells in the crypts of Lieberkuhn migrate to the tips of the villi and are adapted to the body needs of iron by incorporating proportionate quantities of iron into them. The iron binding proteins in the cells decrease the uptake of excess iron. Excess iron is excreted in the faeces, unabsorbed. Loss of iron is a passive process due to haemorrhage haemoglobinuria from intravascular haemolysis.

Three pathways exist for uptake of food iron. Heme from organic sources is digested to be free of globin and enters the cells as metalloporphyrin. Within the cells, iron is released from heme by heme oxygenase and inorganic iron enters the circulation. Inorganic iron from diet is mostly ferric iron, which either enters the cells through the integrin mobilferrin pathway or is reduced to the ferrous state and enters via the divalent metal transporter 1. The proteins of both these pathways interact with para-ferritin within the cells.

Excess iron is stored as ferritin to protect the cell from oxidative damage. Entry of iron into the circulation from the cells is facilitated by proteins ferroportin and hephaestin. The intestinal cells are given a feedback by a reverse transport of iron from the plasma to the cell using a holotransferrin receptor.

Most iron delivered to non intestinal cells is bound to transferrin, via the classical transferrin receptor pathway and a pathway independent of the receptor. Substances that diminish the absorption of ferrous and ferric iron include oxalates, phosphates, carbonates and tannates. Ascorbic acid increases the absorption of ferric and ferrous iron but has little effect on the absorption of heme iron.



(N. HARIHARASUBRAMANIAN MD, PHD)



 The Antiseptic <small>Estd. 1904</small> <small>A MONTHLY JOURNAL OF MEDICINE AND SURGERY</small>	Professional Publications (P) Ltd., Annual Subscription Tariff	 Health <small>Estd. 1923</small> <small>ISSN 0017 - 8861</small> <small>A JOURNAL DEVOTED TO HEALTHFUL LIVING</small>
--	---	---

Particulars	Printed Copy	E-Magazine	Both Print & E Copies	No. of Issues
The Antiseptic	₹ 1200/-	₹ 1180/-* (1000+GST Rs.180)	₹ 2180/- (2000+GST Rs.180)	12
Health	₹ 240/-	₹ 236/-* (200+GST Rs.36)	₹ 436/- (400 + GST Rs.36)	12

For Payment Through NEFT		Send your Subscription to:
Bank Name	City Union Bank Ltd.(CUB)	PROFESSIONAL PUBLICATIONS (P) LTD, NO. 21. "LAKSHMI", SATHYASAI NAGAR, MADURAI-625003 Ph : 0452 269 2939 / 437 8300 / +91 72000 84864 Email : admin@theantiseptic.in
Branch	TVS Nagar, Madurai-625003	
Account No	268109000188090	
IFSC Code	CIUB0000268	

I enclose Rs..... by Cheque / D.D.
 No.dated..... in favour of
 PROFESSIONAL PUBLICATIONS (P) LTD., Payable at Madurai.

Name :
 Speciality :
 Address :

 Tel. : State: :.....
 Pin Code :;
 Landline with
 STD Code :;
 Mobile :;
 Email ID. :.....;

Please enlist my subscription from _____ issue. (* for E-Magazine 18% GST is inclusive.)

Note: If subscription is paid through online (NEFT / IMPS / UPI), please inform us your payment details through Email admin@theantiseptic.in or by submitting **“Online payment intimation form”** which is available in our website “www.theantiseptic.in”

For Advertisement Contact : +91 72000 84864/ 99948 85497 For Email :- admin@theantiseptic.in



Probiotics: Are they risk-free?

SANJAY AGRAWAL

Introduction:

In 2001, the Food and Agriculture Organization of the United Nations and the World Health Organization (WHO) defined probiotics as live microorganisms which, if administered in an adequate amount, confer a health benefit to the host. This definition was maintained by the International Scientific Association for Probiotics and Prebiotics (ISAPP) in 2013.

The term probiotic can be subcategorized to include probiotic drugs, probiotic foods (e.g., foods, food ingredients, and dietary supplements), direct-fed microbials (probiotics for animal use), and designer probiotics (genetically modified probiotics)¹

In the United States, probiotics are considered to be foods or biologics, depending on their intended use. Regardless of how a probiotic is currently marketed, when it is intended to prevent or treat a disease or abnormal condition, it becomes a “drug.” According to an FDA working definition, probiotics are classified as “live biotherapeutics”: “live microorganisms with an intended therapeutic effect in humans, including bacteria and yeast used in disease prevention or treatment, intended local or regional action.” It includes “probiotics for clinical use”²

New species and more specific strains of bacteria are constantly

being sought for development of novel probiotic products. The incorporation of novel bacterial strains into foods and therapeutic products requires reconsideration of the procedures for safety assessment and their safety cannot be assumed. Probiotic products which claim specific nutritional, functional or therapeutic characteristics blur the boundaries between food, dietary supplement or medicine and both their efficacy and safety should be carefully assessed.

Probiotics : Regulatory Status

Depending on the intended use of a probiotic, whether as a drug or a dietary supplement, regulatory requirements differ. According to the Food and Drug Administration (FDA) definition, a drug is an article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease.

If a probiotic is intended for use as a drug, then it must undergo the regulatory process as a drug, which is similar to that of any new therapeutic agent. An Investigational New Drug application must be submitted and authorized by FDA before an investigational or biological product can be administered to humans. The probiotics drug must be proven safe and effective for its intended use before marketing.

If a probiotic is intended for use as a dietary supplement, it is placed under the umbrella of “foods,” and as such is regulated by FDA’s Center for Food Safety and Applied Nutrition. A dietary supplement is defined by the Dietary Supplement Health and Education Act (DSHEA) of 1994

as a product taken by mouth that contains a “dietary ingredient” intended to supplement the diet. Supplements must contain >1 of the following dietary ingredients: a vitamin; a mineral; an herb or other botanical (excluding tobacco); an amino acid; a dietary substance for use by persons to supplement the diet by increasing the total dietary intake; a concentrate, metabolite, constituent, extract; or combination of any of the above. Also, since implementation of the Dietary Supplement and Non-prescription Drug Consumer Protection Act in 2006, manufacturers and distributors of dietary supplements have been required to record and forward to FDA any directly received reports of serious adverse events associated with use of their products.

In contrast to drugs, dietary supplements do not need FDA approval before being marketed. However, manufacturers need to notify FDA before marketing a product. According to DSHEA, the manufacturer is responsible for determining that the dietary supplements that it manufactures or distributes are safe and that any representations or claims made about them are substantiated by adequate evidence to show that they are not false or misleading; the manufacturers need not provide FDA with evidence that substantiates the safety or purported benefits of their products, either before or after marketing.

In Australia, probiotics marketed for specific health benefits require premarket review by the Therapeutic Goods Administration and are usually

Dr. Sanjay Agrawal,
Leading Pharmaceutical Consultant and Editor-in-
Chief of IJMToday,
6/146, Malviya Nagar, Jaipur -302017. Rajasthan.

Specially Contributed to "The Antiseptic"
Vol. 116 No. 4 & P : 07 - 11

regulated as complementary medicines. In Japan, those probiotic products marketed for a specified health use also require formal premarket review by the Health Ministry.

Probiotic Safety: Existing guidelines

In recent years several organisations have formulated approaches to assess the safety of probiotics. The Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food, proposed a framework consisting of strain identification and functional characterisation, followed by safety assessment and Phase 1, 2 and 3 human trials. It recommended that probiotic foods be properly labelled with the strain designation, minimum numbers of viable bacteria at the end of shelf-life, storage conditions and manufacturer's contact details.

The Working Group suggested the following minimum tests to ensure safety:

- Determination of antibiotic resistance patterns
- Assessment of metabolic activities (e.g. D-lactate production, bile salt deconjugation)
- Assessment of side-effects during human studies.
- Post-market epidemiological surveillance of adverse incidents in consumers.
- If the strain being evaluated belongs to a species known to be either a mammalian toxin producer or to have haemolytic potential; it must be tested for toxin production or haemolytic activity.

The European Food Safety Authority (EFSA) has proposed a scheme based on the concept of Qualified Presumption of Safety (QPS)³

Broadly the characteristics to be evaluated for QPS approval are:

- Unambiguous identification at the claimed taxonomic level.
- Relationship of taxonomic identity to existing or historic nomenclature.
- Degree of familiarity with organism, based on weight of evidence.
- Potential for pathogenicity to humans and animals and the end use of the micro-organism.

The Center for Biologics Evaluation and Research (CBER), which regulates human biologics, recommends that safety studies also assess the antibiotic susceptibility of the strain, adherence, colonization, pathogen binding inhibition, duration of fecal shedding, potential translocation across the gut lumen under certain circumstances, and adequate attenuation, inactivation, and/or control for reversion to toxicity or virulence.

Since development of these guidelines, only a few manufacturers have conducted small, randomized, controlled studies in humans to prove efficacy and safety of their products. More manufacturers should take on the responsibility of providing information to consumers and clinicians about the type and extent of safety assessments that have been conducted on their products.

Probiotics: Potential Risks

Probiotics are often regulated as dietary supplements rather than as pharmaceuticals or biological products. Thus, there is usually no requirement to demonstrate safety, purity, or potency before marketing probiotics. The safety of a commercially available probiotic product depends not only on the probiotic organism but

on the other constituents of the product, be it a food or medicinal formulation.

As live microbial products, probiotics have several potential sources of risk as mentioned below⁴

1. Intrinsic toxicity (e.g., a dangerous bacterium),
2. Intrinsic variation (e.g., virulent variants of the same bacterial species),
3. Product misidentification,
4. Product mislabeling,
5. Contamination, and
6. Adulteration

Probiotics may be responsible for four types of side effects in susceptible individuals: systemic infections, harmful metabolic activities, excessive immune stimulation, and gene transfer.⁵

Infection

The most important area of concern with probiotic use is the risk of sepsis. One theoretical concern with the safety of probiotics is that some have been designed or chosen to have good adherence to the intestinal mucosa, and this is considered important for their mechanism of action. Adherence to the intestinal mucosa may also increase bacterial translocation and virulence. The most potent probiotics, therefore, may have increased pathogenicity. The relation between mucosal adhesion and pathogenicity in *Lactobacillus* spp. is supported by the finding that blood culture isolates of *Lactobacillus* spp. adhere to intestinal mucosa in greater numbers than do isolates from human feces or dairy 4 products⁶

Patients with any of the following risk factors are at increased risk of developing sepsis following use of probiotics:

1. Immune compromise, including a debilitated state or malignancy
2. Premature infants
3. Central Venous Catheter
4. Impaired intestinal epithelial barrier, eg, diarrheal illness, intestinal inflammation
5. Administration of probiotic by jejunostomy
6. Concomitant administration of broad spectrum antibiotics to which probiotic is resistant
7. Probiotics with properties of high mucosal adhesion or known pathogenicity
8. Cardiac valvular disease (Lactobacillus probiotics only)

Deleterious metabolic activities

The GI microflora plays an important role in many metabolic activities, such as digestion of complex carbohydrates, lipid metabolism, and glucose homeostasis⁷. There is therefore a theoretical risk of adverse metabolic effects from manipulation of the microflora with the use of probiotics. The likelihood of significant adverse effects in this regard seems low as probiotic studies to date have not shown significant adverse effects on growth or nutrition⁸

Immune deviation or excessive immune stimulation

The GI microflora plays an important role in a range of immune functions, including antibody production, the development and persistence of oral tolerance to food antigens, and the formation of germinal centres within lymphoid follicles⁹. This crucial role of the GI microflora in normal immune development suggests that manipulations designed to alter the microflora may have significant immunomodulatory effects. The long-term effects of these manipulations on the host

is difficult to predict, and adverse effects on immune development remain a possibility. This is particularly relevant with use of probiotics in neonates and in pregnant women.

Gene Transfer

Whether resistance genes can be transferred by a probiotics organism to the endogenous flora, or vice versa, and the impact this would have on antibiotic treatment has yet to be elucidated.

Lactic acid bacteria are naturally resistant to many antibiotics by virtue of their structure or physiology. In most cases the resistance is not transferable. However, it is possible for plasmid-associated antibiotic resistance to spread to other species and genera. Studies with lactic acid bacteria, have demonstrated presence of plasmids with antibiotic-resistance genes, including genes encoding resistance to tetracycline, erythromycin and chloramphenicol. These resistance plasmids have been found in *L. reuteri*, *L. fermentum*, *L. acidophilus*, and *L. plantarum* raw meat, silage, and feces of animals¹⁰

Even though probiotics colonize the human intestine transiently, concern exists regarding the possible transfer of antimicrobial resistance from probiotic strains to more pathogenic bacteria in the intestinal microbiota. Many *Lactobacillus* strains are naturally resistant to vancomycin, which raises concerns regarding the possible transfer of such resistance to more pathogenic organisms, particularly enterococci and *Staphylococcus aureus*.

Safety of Probiotics: Review of Current Evidence

Despite increasing scientific interest in probiotics and their widespread and growing use, very

few properly conducted clinical trials have studied their short-term and long-term safety.

Majority of the published clinical trials conducted with probiotics have included small number of patients per trial, have used a variety of probiotic strains and wide range of daily doses, and even the duration of administration among different trials is highly variable. This makes proper assessment of efficacy and safety of probiotics difficult.

In 2011, a report was released by the Agency for Healthcare Research and Quality (AHRQ) based on research sponsored by the National Institutes of Health and the FDA and conducted by the Southern California Evidence-based Practice Centre reviewing the safety of probiotics. The report was an exhaustive review of the literature including 622 studies of organisms from 6 genera: *Lactobacillus*, *Bifidobacterium*, *Saccharomyces*, *Streptococcus*, *Enterococcus*, and *Bacillus*. The authors of the report concluded that, the vast majority of the existing published studies simply have not adequately assessed and reported on safety of probiotics. Even when assessments are made, these are inconsistent.¹¹

The most commonly reported side effects of probiotics from short-term studies are related to the gastro-intestinal tract. These side effects include: abnormal bowel movements, bloating, flatulence, gurgling, and stomach aches.

A systematic review of original articles published between 1976 and 2018 was carried out to study infectious complications related to probiotic ingestion.¹² A search of PubMed, SciELO and Scopus databases revealed

60 case reports and 7 case series, making up a total of 93 patients. The results of this systemic review are summarised below:

Occurrence of infectious complications:

Fungemia was most commonly observed complication. There were 35 (37.6%) cases of fungemia. Sepsis was identified in 29 (31.2%) patients and bacteraemia was reported in 19 (20.4%) cases. This was followed by endocarditis and abscess, with 4 and 3 cases, respectively. Pneumonia, pleural empyema and septic arthritis were present in only one case each.

Probiotic microorganisms involved in infectious complications:

Saccharomyces spp.

Among the 93 cases, 47 (50.5%) were due to *Saccharomyces*. In 5 patients, *Saccharomyces boulardii* (*S. boulardii*) was isolated from blood, in 41 cases *S. cerevisiae* was isolated from biological samples and in only one case the species was not identified. In 27 cases, the probiotic microorganisms in the medications were compatible with the isolates found in the blood samples of the patient.

Lactobacillus spp.

Lactobacillus spp. were the etiologic agents in 26 episodes of infectious complications after probiotics use; 14 were identified as *L. rhamnosus*, 4 as *L. acidophilus*, 3 as *L. paracasei*, 1 as *L. casei* and 4 cases were not identified at species level

Bifidobacterium spp.

Of the 12 patients with infectious complications due to *Bifidobacterium* spp., 10 were newborns (9 preterm). *B. longum* was present in 6 cases of infectious complications, followed by *B. infantis* and *B. breve*, with two cases each.

Bacillus spp.

One case series described 4 cases of bacteremia caused by *B. subtilis* associated with the use of probiotics containing these microorganisms; the probiotic was given to reduce the number of diarrheal episodes related to enteral nutrition.

Probiotics: At Risk Population

Although most commercially available probiotic strains are widely regarded as safe, there are significant concerns with respect to safety in particular populations.

According to the FDA following populations are potentially at risk for adverse events with use of probiotics:

1. Immunosuppressed-

anti-rejection medication after stem cell or solid organ transplant, injectable immunosuppressive drugs for autoimmune disease, or corticosteroids (greater than ½ mg per kg body weight or prednisone or its equivalent); chemotherapy or radiation

2. Structural heart disease-

Valve abnormality or replacement, history of endocarditis

3. Potential for translocation of probiotic across bowel wall-

Presence of an active bowel leak, acute abdomen, active intestinal disease including colitis, or significant bowel dysfunction; presence of neutropenia or anticipation of neutropenia after chemotherapy; radiation therapy

4. Pregnant women

Probiotics: Way Forward

To monitor the safety of probiotics, it is important to conduct population-based surveillance for the isolation of probiotic bacteria from patients with infection. There should be knowledge of the susceptibility profile for any strain used in

clinical trials¹³ and facilities to compare the clinically isolated strain with the probiotic strain by use of molecular methods should be readily available. Any trial using a probiotic strain should have active surveillance for cases of infection associated with such use and for the occurrence of other adverse effects.

For greater acceptance and judicious use of probiotics, following information should be generated for each probiotic product:

- Identification and characterization of the probiotic strains
- Its mechanisms of action should be elucidated with proper scientific studies
- Its Clinical effectiveness should be established by properly designed, randomized, blinded, placebo-controlled clinical trials
- The relationship between the dose and duration of probiotic therapy and its clinical effects, on a strain by strain basis should be well documented
- Short-term and long-term safety of probiotic strains
- Risk-benefit analysis : The risks and benefits of probiotic therapy should be compared with existing treatment options
- Accurate labelling and proper storage

Safety of Probiotics: Summary

In view of the increasing use of probiotics as health supplements and therapeutic agents, clinicians need to be aware of the risks and benefits associated with their use.

The use of probiotics cannot be considered risk-free and their safety should be carefully evaluated, as use of probiotics is known to cause bacteremia, fungemia and sepsis in immunocompromised individuals.

Vigilant reporting of adverse events resulting from probiotic use is necessary to establish the safety profile of these agents when they are used in other than healthy populations. Physicians caring for immunocompromised or critically ill patients must be fully aware of these potential serious complications of probiotic use.

Better designed studies are needed to answer questions related to effectiveness and safety of probiotics. Proper risk-benefit analysis of probiotics should be carried out to study their potential for the prevention and treatment of various critical illnesses. (Ref.14)

REFERENCES:

1. Functional Food Reviews. 2009; 1:3–12.
2. Office of Vaccine Research and Review Working Group, Centre for Biologics Evaluation and Research, US Food and Drug Administration
3. European Food Safety Authority, EFSA Colloquium 2 -“Micro-organisms in Food and Feed Qualified Presumption of Safety – QPS”. 2005.
4. Freddie Ann Hoffman: Development of Probiotics as Biologic Drugs. *Clinical Infectious Diseases* 2008; 46:S125–7
5. Robert J Boyle, Roy M Robins-Browne, and Mimi LK Tang Probiotic use in clinical practice: what are the risks? *Am J Clin Nutr* 2006;83:1256–64.
6. Apostolou E, Kirjavainen PV, Saxelin M, et al. Good adhesion properties of probiotics: a potential risk for bacteremia? *FEMS Immunol Med Microbiol* 2001;31:35–9.
7. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host bacterial mutualism in the human intestine. *Science* 2005; 307:1915–20.
8. Saavedra JM, Abi-Hanna A, Moore N, Yolken RH. Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety. *Am J Clin Nutr* 2004; 79:261–7.
9. Gaboriau-Routhiau V, Moreau MC. Gut flora allows recovery of oral tolerance to ovalbumin in mice after transient breakdown mediated by cholera toxin or Escherichia coli heat-labile enterotoxin. *Pediatr Res* 1996; 39: 625–9.).
10. Gevers D, Danielsen M, Huys G, Swings J. Molecular characterization of tet(M) genes in Lactobacillus isolates from different types of fermented dry sausage. *Appl Environ Microbiol* 2003; 69:1270–5.
11. Hempel S, Newberry S, Ruelaz A, et al. Safety of probiotics used to reduce risk and prevent or treat disease. Rockville, MD: Agency for Healthcare Research and Quality, 2011
12. Costa et al. Infectious complications following probiotic ingestion: a potentially underestimated problem? A systematic review of reports and case series. *BMC Complementary and Alternative Medicine* (2018) 18:329
13. Salminen MK, Rautelin H, Tynkkynen S, et al. Lactobacillus bacteremia, species identification, and antimicrobial susceptibility of 85 blood isolates. *Clin Infect Dis* 2006; 42:e35–44.
14. F1000Res. 2016 Mar 29;5. eCollection 2016.



Homocysteine (Hcy) is a sulfhydryl amino acid compound that is generated from protein breakdown and the essential amino acid methionine as it is metabolized to cysteine. Hcy can be metabolized by two major pathways. When methionine is in excess, Hcy is directed to the transsulphuration pathway, where it is irreversibly sulfoconjugated to cysteine by cystathionine B-synthase with vitamin B₆ as a cofactor. Hcy is also remethylated in a methionine – conserving pathway. This process requires methionine synthase, vitamin B₁₂ as a cofactor, and methyltetrahydrofolate as a cosubstrate. The methionine-conserving pathway requires folic acid and methyltetrahydrofolate reductase (MTHFR). There is a strong inverse correlation of plasma Hcy with plasma folate concentration. In contrast to folate, serum vitamin B₁₂ or vitamin B6 levels show only a weak correlation with plasma Hcy. Deficiencies in any of these above enzymes, folic acid, or the cofactors may lead to some degree of hyperhomocysteinemia.

Hypozincemia is associated with cirrhosis and higher incidence of encephalopathy.

Zinc (Zn) is second most abundant trace element in the body. Zn is associated with more than 300 enzymatic functions. It is an important co-factor in urea cycle, has great role in conversation of ammonia to urea. Zn is an important part of natural defence mechanism involving of reactive oxygen species, it also act as an antioxidant, anti apoptotic agent, and anti-inflammatory agent.